Mesoblast Limited (MSB.AX)

1,1000 +0,1100 (+11,11%) Al cierre: 04:10PM AEST

Mesoblast Limited

55 Collins Street
Level 38
Melbourne, VIC 3000
Australia
61 3 9639 6036
https://www.mesoblast.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 83

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)	Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director	1,13M	N/A	1957
Dr. Eric A. Rose M.D.	Chief Medical Officer & Executive Director	956,61k	N/A	1951
Mr. Andrew Chaponnel B.Com.	Interim Chief Finance Officer	N/A	N/A	N/A
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)	General Counsel & Corporate Executive	N/A	N/A	1968
Mr. Roger D. Brown BA	Head of Spinal Orthopedic Disorders	N/A	N/A	N/A
Mr. Michael Schuster BSc, M.B.A., MS	Head of Pharma Partnering	N/A	N/A	1977
Ms. Geraldine Storton B.Sc., M.B.A., MMS	Head of Regulatory Affairs & Quality Management	N/A	N/A	N/A
Mr. Justin Horst B.S.	Head of Manufacturing	N/A	N/A	N/A
Ms. Niva Sivakumar B.Com., L.L.B.	Joint Company Secretary	N/A	N/A	N/A
Mr. Paul Hughes BPHARM	Joint Company Secretary	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en AUD.

Descripción

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Gobierno corporativo

El ISS Governance QualityScore de Mesoblast Limited, a día 29 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 9; Tablero: 6; Derechos de los accionistas: 10; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.